

In the Claims

Claims 1-17 (Canceled).

18. (New) A method for treating a subject with glaucoma comprising the steps of administering a compound or composition containing an agent or molecule, which antagonizes, inhibits, inactivates, reduces, suppresses, and/or limits the release, synthesis, or production from cells of TNF- α thereby treating the subject with glaucoma.

19. (New) The method of claim 18, wherein the compound or composition inhibits the production of TNF- α .

20. (New) The method of claim 18, wherein the compound or composition limits the synthesis or release of TNF- α from cells.

21. (New) The method of claim 21, wherein the cells are immune cells, lymphocytes, glia and neuron cells.

22. (New) The method of claim 21, wherein the compound is thalidomide.

23. The method of claim 18, wherein said compound or composition further comprises a diluent and suitable carrier.

24. The method of claim 18, wherein the compound or composition is administered ocularly, parenterally, transmucosally, transdermally, intramuscularly, intravenously, intradermally, intravascularly, or subcutaneously, intraperitoneally, by topical drops or ointment, periocular injection, systemically by intravenous injection or orally, intracamerally into the anterior chamber or vitreous, via a depot attached to the intraocular lens implant inserted during surgery, or via a depot placed in the eye sutured in the anterior chamber or vitreous.